Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.

Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, Butt ZA, Chong M, Cook D, Alvarez M, Darvishian M, Tyndall M, Krajden M.

J Viral Hepat. 2017 Aug;24(8):624-630. doi: 10.1111/jvh.12684. Epub 2017 Feb 20.

PMID:
28130810
2.

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z.

Aliment Pharmacol Ther. 2014 Sep;40(6):657-75. doi: 10.1111/apt.12871. Epub 2014 Jul 28.

3.

Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.

Beste LA, Green PK, Ioannou GN.

Eur J Gastroenterol Hepatol. 2015 Feb;27(2):123-9. doi: 10.1097/MEG.0000000000000241.

PMID:
25503739
4.

Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.

Alsius M, Ferri MJ, Buxó M, López C, Serra I, Queralt X, Acero D.

Gastroenterol Hepatol. 2019 Feb;42(2):82-89. doi: 10.1016/j.gastrohep.2018.08.005. Epub 2018 Nov 13. English, Spanish.

PMID:
30446175
5.

Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.

Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study.

Liver Int. 2016 Sep;36(9):1275-83. doi: 10.1111/liv.13103. Epub 2016 Mar 24.

PMID:
26928927
6.

Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.

Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

J Manag Care Spec Pharm. 2015 Apr;21(4):308-18.

7.

Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.

Litwin AH, Soloway IJ, Cockerham-Colas L, Reynoso S, Heo M, Tenore C, Roose RJ.

Int J Drug Policy. 2015 Oct;26(10):1014-9. doi: 10.1016/j.drugpo.2015.08.008. Epub 2015 Aug 20.

8.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
9.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
10.

Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.

Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1021-7. doi: 10.1016/j.cgh.2013.03.006. Epub 2013 Mar 21.

PMID:
23524130
11.

Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.

Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study.

J Int AIDS Soc. 2017 Nov;20(3). doi: 10.1002/jia2.25013.

12.

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.

Dieterich D, Nelson M, Soriano V, Arastéh K, Guardiola JM, Rockstroh JK, Bhagani S, Laguno M, Tural C, Ingiliz P, Jain MK, Stern JO, Manero M, Vinisko R, Kort J; STARTVerso4 study group.

AIDS. 2015 Mar 13;29(5):571-81. doi: 10.1097/QAD.0000000000000579.

PMID:
25710287
13.

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA.

PLoS One. 2016 Jan 11;11(1):e0145409. doi: 10.1371/journal.pone.0145409. eCollection 2016.

14.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
15.

Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.

Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH.

Dig Dis Sci. 2015 Apr;60(4):1045-51. doi: 10.1007/s10620-015-3621-0. Epub 2015 Mar 28.

PMID:
25821099
16.

Direct-acting antiviral (DAA) actions in treatment-naïve patients.

Hézode C.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S52-8. doi: 10.1016/S2210-7401(11)70008-0.

PMID:
22248695
17.

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.

Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D; ESCMID European Study Group on Viral Hepatitis.

Liver Int. 2015 Sep;35(9):2090-9. doi: 10.1111/liv.12799. Epub 2015 Feb 23.

PMID:
25650873
18.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.

J Med Econ. 2014 Jan;17(1):77-87. doi: 10.3111/13696998.2013.844159. Epub 2013 Nov 21.

PMID:
24032626
19.

Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.

Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo AL, Gervasoni C, Galli M, Antinori S, Sollima S.

HIV Med. 2017 Apr;18(4):284-291. doi: 10.1111/hiv.12429. Epub 2016 Aug 1.

20.

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.

Bailly F, Pradat P, Virlogeux V, Zoulim F.

Dig Dis. 2015;33(4):613-23. doi: 10.1159/000375359. Epub 2015 Jul 6.

PMID:
26159282

Supplemental Content

Support Center